List view / Grid view
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
Researchers have developed an artificial intelligence to identify the best potential antibody drug from groups of up to a few thousand.
The newest version of the Unified Data Model (UDM) project has been released, allowing R&D scientists to access information on compound synthesis and testing.
The structure of a key receptor involved in tumour metastasis has been imaged in a study, providing opportunities to develop cancer treatments.
Researchers have successfully created a multi-organ in vitro model to test toxicity and efficacy of drugs.
The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial…
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
Medicinal marijuana is used frequently as a painkiller for a variety of ailments and diseases yet its psycho active side effects are seen by many as a significant disadvantage.
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The Treponema pallidum assay is intended as an aid in the diagnosis of syphilis infection. The Roche Syphilis treponemal antibody test offers several...
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
20 August 2015 | By Victoria White
Janus Biotherapeutics has entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor...
19 August 2015 | By Victoria White
Roche has signed a definitive agreement to acquire Kapa Biosystems, strengthening Roche's next-generation sequencing product offerings...
18 August 2015 | By The European Antibody Congress
The European Antibody Congress takes place 9-11 November 2015 at the Congress Centre, Basel...
22 July 2015 | By Victoria White
Roche’s Elecsys immunoassay, a diagnostic test to detect antibodies against Human T-lymphotropic virus (HTLV) type I or II, is now available on the market...
